SGLT2 INHIBITORS BEYOND DIABETES A RETROSPECTIVE AUDIT OF PRESCRIBING PATTERNS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION

Mehak Nazeem; Haleema Iqbal ,; Nayab Nisar; Saifullah,

Authors

Mehak Nazeem Medical Student, Samarkand state medical university, Uzbekistan ,
Haleema Iqbal , Medical Student, Samarkand state medical university Uzbekistan
Nayab Nisar Medical Student , Samarkand state medical university, Uzbekistan ,
Saifullah, Medical Student, Samarkand state medical university, Uzbekistan ,

Abstract

Heart failure with preserved ejection fraction (HFpEF) constitutes a substantial and increasing proportion of heart failure cases worldwide, with historically limited evidence-based therapeutic options. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, initially developed for the management of type 2 diabetes mellitus, have demonstrated significant cardiovascular benefits, including reductions in heart failure hospitalizations and improvement in functional outcomes, irrespective of glycemic status. This retrospective audit aimed to evaluate prescribing patterns of SGLT2 inhibitors in patients with HFpEF, with particular emphasis on their utilization beyond diabetes.

References

1. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Philadelphia: Elsevier; 2022.

2. Harrison’s Principles of Internal Medicine. 21st ed. New York: McGraw Hill; 2022.

3. API Textbook of Medicine. 11th ed. Mumbai: Association of Physicians of India; 2019.

4. European Society of Cardiology. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

5. American Heart Association / American College of Cardiology. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

6. Stefan D. Anker, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021;385:1451–1461.

7. Scott D. Solomon, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. 2022;387:1089–1098.

8. National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: diagnosis and management. 2021.